Prevalence, incidence, and mortality associated with sarcoidosis over three decades in the HUNT Study in Norway - 24/04/25
, A.H. Henriksen c, d , H. Sorger d, e , T. Naustdal e , T.I. Lund Nilsen d, f , P.R. Romundstad g , A. Langhammer h , S. Romundstad a, e Abstract |
The incidence and prevalence of sarcoidosis vary globally, with the highest estimates in Scandinavia. Since there are no recent data from Norway, we aimed to investigate the prevalence, incidence and mortality of sarcoidosis over three decades among participants in the population-based HUNT Study.
The study population included participants in the first three surveys of the HUNT Study (HUNT1,1984–86; HUNT2,1995-97 and HUNT3, 2006–08). We identified 365 participants with sarcoidosis. Approximately 10 % of sarcoidosis patients were identified by x-ray screening in HUNT1, the remaining by linkage to hospital records. We randomly selected four age, sex and survey-matched participants without sarcoidosis for each of the 310 participants with incident sarcoidosis and followed these from diagnosis until death or end of follow-up in 2023. We used Cox regression to estimate adjusted hazard ratios (HRs) with 95 % confidence intervals (CIs) of death from all-causes.
From 1984 to 2018, annual prevalence increased from 0.54 (95 % CI 0.41, 0.72) to 1.34 (95 % CI 1.08, 1.64) percent, while incidence rate increased from 12.1 (95 % CI 9.5, 14.7) to 18.7 (95 % CI 13.4, 24.0) per 100 000/year. The largest increase was seen in non-Lofgren syndrome (nLS). People with nLS had more than twice the mortality compared to people without sarcoidosis (HR 2.4; 95 % CI, 1.9, 3.1). There was no clear association between Lofgren syndrome and overall mortality.
Sarcoidosis prevalence and incidence appeared to increase, particularly for nLS. Mechanisms leading to increased mortality in nLS needs to be further addressed.
Le texte complet de cet article est disponible en PDF.Highlights |
Highlights: Prevalence, incidence, and mortality associated with sarcoidosis over three decades in the HUNT Study in Norway.
• | In sarcoidosis, substantial phenotypic variability challenges estimation of prognosis. |
• | Stratification by disease phenotype, like Lofgren and non-Lofgren syndrome, could improve the understanding of mortality in sarcoidosis. |
• | Compared to a matched, non-sarcoidosis control group, there was an increased mortality in non-Lofgren sarcoidosis, HR 2.4 (1.9, 3.1). |
Plan
Vol 241
Article 108049- mai 2025 Retour au numéro
Article précédent
- A retrospective cohort study of children diagnosed with Cystic Fibrosis after implementation of a newborn screening program in Turkey
- Handan Kekeç, Tuğba Şişmanlar Eyüboğlu, Ayşe Tana Aslan, Zeynep İlkşen Hocoğlu, Ebru Yalçın, Birce Sunman, Burcu Çapraz Yavuz, Velat Şen, Suat Savaş, Ayşe Ayzıt Kılınç, Azer Kılıç Başkan, Hakan Yazan, Gökçen Ünal, Yakup Canıtez, Nihat Sapan, Figen Gülen, Gökçen Kartal Öztürk, Özlem Keskin, Elif Arık, Mehmet Köse, Ali Ersoy, Derya Ufuk Altıntaş, Mahir Serbes, Abdurrahman Erdem Başaran, Ayşen Bingöl, Ali Özdemir, Meral Barlık, Gökşen Dilşa Tuğcu, Işıl Bilgiç, Hülya Anıl, Beste Özsezen, Merve Nur Tekin, Hasan Yüksel, Gönül Çaltepe, Melih Hangül, Zeynep Gökçe Gayretli Aydın, Mehmet Kılıç, Mina Hızal, Nilay Baş İkizoğlu, Gizem Özcan, Nagehan Emiralioğlu, Güzin Cinel, Sevgi Pekcan, Erkan Çakır, Uğur Özçelik, Deniz Doğru
- Early-life pneumonia and subsequent risk of respiratory disease among commercial-insured and medicaid-insured children with and without high-risk conditions
- Ahuva Averin, Stephen I. Pelton, Derek Weycker, Liping Huang, Jeffrey Vietri, Maria J. Tort, Adriano Gerardo Arguedas Mohs, Alejandro Cane, Mark H. Rozenbaum, Rotem Lapidot
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?